About the webinar:
Since the development of the super immunodeficient CIEA NOG mouse® in the early 2000s enabled improved humanized immune system (HIS) mice, HIS models have been widely adopted in immuno-oncology research. Because HIS mice can support both tumor cell line xenografts (CDX) or patient-derived xenografts (PDX) in addition to relevant human immune cells, they are widely used in the preclinical evaluation of immune-modulating therapeutics. While foundational HIS models primarily supported lymphoid cells, second-generation host strains expressing human cytokines made HIS models with human innate and adaptive cells possible. While researchers can now study immune-modulating therapeutics in the context of interactions between human myeloid and lymphoid lineages, HIS mouse engraftment profiles are host strain-specific and can be influenced by the engraftment protocol and donor variability.
This webinar will discuss humanization of the NOG-EXL and hIL-6 NOG host strains, which both support a range of human cell types including myeloid and lymphoid lineages, along with considerations for successful efficacy evaluation of IO therapies in HIS models. This webinar is part two of a three-part series - click here to explore this educational series.
View this webinar to:
- Gain a general understanding of humanized immune system mouse models that can support both innate and adaptive human immune cells
- Learn about differences between super immunodeficient mouse models and how engraftment strategies can influence immune cell populations
- Understand how to select the best humanized immune system model based on your needs for specific cell populations
- How to apply HIS models to cutting-edge immuno-oncology questions